25D-NBOMe

25D-NBOMe (2-(2,5-dimethoxy-4-methylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine) is a synthetic psychedelic phenethylamine of the NBOMe series, structurally analogous to 2C-D with the addition of an N-(2-methoxybenzyl) group. It is among the least studied and least prevalent of the recognized NBOMe compounds, and as a result, specific pharmacological data, dose ranges, and safety profiles are less well-characterized than for 25I-NBOMe, 25B-NBOMe, or 25C-NBOMe.

Like all NBOMe compounds, 25D-NBOMe is expected to be active at microgram doses, active only via sublingual or buccal routes, and to produce a psychedelic experience through potent 5-HT2A agonism. The 4-methyl substitution on the phenyl ring (as compared to the more common 4-iodo, 4-bromo, and 4-chloro variants) is associated in the 2C family with a somewhat gentler and shorter-acting profile, and this may hold for the NBOMe variant — though this inference should not be relied upon clinically.

Community-sourced reports describe 25D-NBOMe experiences as broadly similar to other NBOMe compounds, with intense visuals, cognitive distortion, and a prominent stimulant component. The lack of established safety data makes 25D-NBOMe particularly hazardous for recreational use — users cannot rely on an established literature to understand its dose-response relationship, and the same fundamental hazards of NBOMe toxicity (vasoconstriction, hyperthermia, seizure potential) should be assumed until demonstrated otherwise.